U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 155 results

Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Ritlecitinib is an orally administered, covalent small-molecule selective dual inhibitor of JAK3 and the TEC kinase family. In vitro studies showed ritlecitinib covalently binds to JAK3 and is more than 10 000 times more potent against JAK3 than agai...
Status:
US Approved Rx (2023)
First approved in 2022

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Trofinetide (NNZ 2566), a proprietary small molecule analogue of glycine-proline-glutamate [Glypromate®], is being developed by Neuren Pharmaceuticals and Acadia Pharmaceuticals for the treatment of brain injuries, fragile X syndrome, Rett syndrome. ...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Difelikefalin (Korsuva™) is a synthetic peptide agonist of the kappa opioid receptor being developed by Cara Therapeutics for the treatment of pruritus. In August 2021, intravenous difelikefalin was approved in the USA for the treatment of moderate-t...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ibrexafungerp (BREXAFEMME®) is an orally active triterpenoid antifungal drug being developed by SCYNEXIS, Inc. for the treatment of fungal infections. The inhibition of β-1,3-D glucan synthetase by ibrexafungerp compromises the integrity of fungal ce...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ABSOLUTE)



Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare Pharmaceuticals for the treatment of diabetic kidney disease (DKD) and heart fa...
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cabotegravir is an investigational drug that is being studied for the treatment and prevention of HIV infection. Cabotegravir belongs to a class (group) of HIV drugs called integrase inhibitors. Integrase inhibitors block an HIV enzyme called integra...
Status:
US Approved Rx (2020)
First approved in 2020

Class (Stereo):
CHEMICAL (ACHIRAL)



Fostemsavir (BMS-663068) is an investigational attachment inhibitor with a unique mechanism of action. It is a prodrug of temsavir, which binds to HIV envelope glycoprotein 120 (gp120), thereby preventing viral attachment to the host CD4 cell surface...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ACHIRAL)



Tafamidis meglumine (Vyndaqel®, Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairme...
Status:
US Approved Rx (2019)
First approved in 2019

Class (Stereo):
CHEMICAL (ACHIRAL)



Pitolisant (INN) or tiprolisant (USAN) is a histamine receptor inverse agonist/antagonist selective for the H3 subtype. It has stimulant and nootropic effects in animal studies and may have several medical applications, having been researched for the...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cannabidiol is the major nonpsychoactive ingredient in cannabis. Cannabidiol demonstrates a range of effects that may be therapeutically useful, including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psy...